Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Epoprostenol
Drug ID BADD_D00788
Description A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.
Indications and Usage For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Marketing Status approved
ATC Code B01AC09
DrugBank ID DB01240
KEGG ID D00106
MeSH ID D011464
PubChem ID 5282411
TTD Drug ID D0V0IX
NDC Product Code 66215-402; 62756-060; 66215-403; 62287-123; 62756-059
UNII DCR9Z582X0
Synonyms Epoprostenol | Epoprostanol | Prostaglandin I2 | Prostacyclin | Prostaglandin I(2) | Veletri | Epoprostenol Sodium | Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer | Flolan
Chemical Information
Molecular Formula C20H32O5
CAS Registry Number 35121-78-9
SMILES CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Terminal state08.01.03.0790.000123%Not Available
Live birth18.08.02.0070.000403%Not Available
Spinal cord ischaemia24.04.06.040; 17.10.01.0180.000329%Not Available
Right ventricular hypertrophy02.04.02.0340.000082%Not Available
Portal hypertensive gastropathy24.08.06.006; 09.01.06.022; 07.12.01.0070.000082%Not Available
Right ventricular dysfunction02.04.02.0330.000082%
Arterial haemorrhage24.07.01.0630.000082%Not Available
Acute right ventricular failure02.05.03.0030.000082%Not Available
Delivery18.08.02.0060.000123%Not Available
Internal haemorrhage24.07.01.0720.000164%Not Available
Administration site odour12.07.04.027; 08.02.04.0270.000181%Not Available
Catheter site dermatitis23.03.04.043; 12.07.02.015; 08.02.02.0150.000082%Not Available
Catheter site discharge12.07.02.016; 08.02.02.0160.001308%Not Available
Catheter site discolouration08.02.02.017; 23.03.03.074; 12.07.02.0170.000181%Not Available
Catheter site irritation12.07.02.022; 08.02.02.0220.000123%Not Available
Catheter site pruritus12.07.02.025; 08.02.02.025; 23.03.12.0110.001933%Not Available
Catheter site rash23.03.13.024; 12.07.02.026; 08.02.02.0260.000748%Not Available
Catheter site scab23.03.03.075; 08.02.02.027; 12.07.02.0270.000222%Not Available
Catheter site swelling12.07.02.005; 08.02.02.0050.000921%Not Available
Catheter site vesicles23.03.01.032; 12.07.02.030; 08.02.02.0300.000485%Not Available
Catheter site warmth12.07.02.031; 08.02.02.0310.000123%Not Available
Coronary artery compression24.04.04.029; 12.02.01.034; 02.02.01.0180.000082%Not Available
Disease complication08.01.03.0870.000288%Not Available
Endocrine ophthalmopathy14.11.01.051; 10.04.08.012; 06.09.04.008; 05.02.02.0080.000082%Not Available
Graves' disease10.04.08.014; 06.09.04.009; 05.02.02.0090.000452%Not Available
Illness08.01.03.0910.000304%Not Available
Infusion site discolouration23.03.03.084; 12.07.05.026; 08.02.05.0260.000082%Not Available
Lid lag17.17.02.016; 06.05.01.006; 05.02.01.0060.000082%Not Available
Lung opacity22.12.01.0060.000123%Not Available
Plethoric face24.03.04.017; 23.03.03.095; 08.01.03.0970.000082%Not Available
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages